Adjuvant therapy with imatinib for an incompletely resected multilobular tumour of bone in a dog

https://doi.org/10.17221/85/2021-VETMEDCitation:

Lee SH, Kim DH, Bae K, Jeong SW, Yoon KA, Yoon HY, Do SH, Kim B, Kim JH (2022): Adjuvant therapy with imatinib for an incompletely resected multilobular tumour of bone in a dog. Vet Med-Czech 67, 590–597.

download PDF

A 5-year-old neutered male Shiba Inu dog presented with a history of oral bleeding, dysphagia, and depression for 3 weeks. The physical examination revealed a firm mass in the right caudal palatal region along the level of PM4–M2. On the computed tomography, the mass was round-to-oval in shape and 22 mm × 30 mm × 15 mm in size. The mass contained multiple bone attenuated materials with a palatal bone lysis of 4 mm × 6 mm. A complete resection of the mass was proposed; however, the owner declined due to the risk of complications associated with the radical surgery. Therefore, a palliative resection and biopsy of the mass were performed. On the histological examination, the mass was diagnosed as grade 2 multilobular tumour of bone (MTB). Since the mass was incompletely resected, adjuvant therapy was pursued along with targeted therapy using a tyrosine kinase inhibitor. The tumour cells showed overexpression of the receptor of tyrosine kinase for c-KIT, PDGFR-α, PDGFR-β, and FGFR1 compared to normal tissue cells. Additionally, the cytotoxic effect of imatinib on the MTB cells was confirmed in vitro. Four weeks postoperatively, the administration of imatinib and carprofen was initiated and continued for 259 days. The patient maintained a good functional outcome for 306 days after the initial presentation.

References:
Banks TA, Straw RC. Multilobular osteochondrosarcoma of the hard palate in a dog. Aust Vet J. 2004;82(7):409-12. https://doi.org/10.1111/j.1751-0813.2004.tb11127.x
 
Barnes G, Bulusu VR, Hardwick RH, Carroll N, Hatcher H, Earl HM, Save VE, Balan K, Jamieson NV. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg. 2005;3(3):206-12. https://doi.org/10.1016/j.ijsu.2005.04.001
 
Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J. 2015 Aug;205(2):180-8. https://doi.org/10.1016/j.tvjl.2014.12.015
 
Buchdunger E, O’Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002 Sep;38(Suppl_5):S28-36. https://doi.org/10.1016/S0959-8049(02)80600-1
 
Cook S, Civello A, Lam R, Fenn J, Neilson D, Priestnall S, Decker S. Rapid postoperative recurrence of a cranial multilobular tumor of bone in a young dog. Clin Case Rep. 2017 Oct 30;5(12):1995-9. https://doi.org/10.1002/ccr3.1243
 
Dernell WS, Straw RC, Cooper MF, Powers BE, LaRue SM, Withrow SJ. Multilobular osteochondrosarcoma in 39 dogs: 1979–1993. J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):11-8. https://doi.org/10.5326/15473317-34-1-11
 
Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):985-8. https://doi.org/10.1111/j.1939-1676.2008.00132.x
 
Kim GH, Kim JH. Effective palliative treatment of recurrent soft tissue sarcoma in a dog using imatinib mesylate (Gleevec®). Vet Med-Czech. 2018;63(11):532-6. https://doi.org/10.17221/34/2018-VETMED
 
Kim JH, Yoon H, Yoon HY, Eom K, Sung HJ, Kim JH. Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor. Can Vet J. 2018 Apr;59(4):367-72.
 
Lascelles BD, Thomson MJ, Dernell WS, Straw RC, Lafferty M, Withrow SJ. Combined dorsolateral and intraoral approach for the resection of tumors of the maxilla in the dog. J Am Anim Hosp Assoc. 2003 May-Jun;39(3):294-305. https://doi.org/10.5326/0390294
 
London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med. 2009 Aug;24(3):106-12. https://doi.org/10.1053/j.tcam.2009.02.002
 
MacLellan RH, Rawlinson JE, Rao S, Worley DR. Intraoperative and postoperative complications of partial maxillectomy for the treatment of oral tumors in dogs. J Am Vet Med Assoc. 2018 Jun 15;252(12):1538-47. https://doi.org/10.2460/javma.252.12.1538
 
Nakahara N, Mitchell K, Straw R, Kung M. Hard palate defect repair by using haired angularis oris axial pattern flaps in dogs. Vet Surg. 2020 Aug;49(6):1195-202. https://doi.org/10.1111/vsu.13435
 
Poradowski D, Obminska-Mrukowicz B. Effect of selected nonsteroidal anti-inflammatory drugs on the viability of canine osteosarcoma cells of the D-17 line: In vitro studies. J Vet Res. 2019 Sep 13;63(3):399-403. https://doi.org/10.2478/jvetres-2019-0051
 
Straw RC, LeCouteur RA, Powers BE, Withrow SJ. Multilobular osteochondrosarcoma of the canine skull: 16 cases (1978–1988). J Am Vet Med Assoc. 1989 Dec 15;195(12):1764-9.
 
Tuohy JL, Worley DR, Wustefeld-Janssens BG, Mickelson MA, Ehrhart NP, Seguin B. Bilateral caudal maxillectomy for resection of tumors crossing palatal midline and use of the angularis oris axial pattern flap for primary closure or dehiscence repair in two dogs. Vet Surg. 2019 Nov;48(8):1490-9. https://doi.org/10.1111/vsu.13252
 
Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci. 2006 Jun;80(3):308-16. https://doi.org/10.1016/j.rvsc.2005.07.013
 
Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med. 2002 Jan;8(1):17-23. https://doi.org/10.1016/S1471-4914(01)02217-1
 
download PDF

© 2022 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti